Sec Form 4 Filing - Pfost Dale R @ eXegenics Inc - 2007-03-29

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Pfost Dale R 2. Issuer Name and Ticker or Trading Symbol eXegenics Inc [ EXEG] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President (Last) (First) (Middle) EXEGENICS INC., 4400 BISCAYNE BOULEVARD, SUITE 900 3. Date of Earliest Transaction (MM/DD/YY) 03/29/2007 (Street) MIAMI, FL33137 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $.01 per share 03/29/2007 J( 1 ) 1,687,261 A $ 0 1,687,261 D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series C Convertible Preferred Stock $ 0 03/29/2007 J( 1 ) 5,189 ( 3 ) ( 3 ) Common Stock 518,900 $ 0 5,189 D Warrant (Right to Buy) $ 0.002 03/29/2007 J( 1 ) 64,868 ( 4 ) 03/27/2017 Common Stock 64,868 $ 0 64,868 D Warrant (Right to Buy) $ 0.6728 03/29/2007 J( 1 ) 68,852 ( 4 ) 03/27/2017 Common Stock 68,852 $ 0 68,852 D Warrant (Right to Buy) $ 0.8473 03/29/2007 J( 1 ) 68,852 ( 4 ) 03/27/2017 Common Stock 68,852 $ 0 68,852 D Warrant (Right to Buy) $ 1.0466 03/29/2007 J( 1 ) 68,852 ( 4 ) 03/27/2017 Common Stock 68,852 $ 0 68,852 D Stock Option (Right to Buy) $ 31.8 03/29/2007 J( 1 ) 7,317 ( 5 ) 09/24/2014 Series C Convertible Preferred Stock 7,317 $ 0 7,317 D Stock Option (Right to Buy) $ 0.04 03/29/2007 J( 1 ) 430,722 ( 6 ) 12/11/2013 Common Stock 430,722 $ 0 430,722 D Stock Option (Right to Buy) $ 0.04 03/29/2007 J( 1 ) 225,740 ( 5 ) 09/24/2014 Common Stock 225,740 $ 0 225,740 D Stock Option (Right to Buy) $ 0.04 03/29/2007 J( 1 ) 1,297,357 ( 7 ) 02/15/2015 Common Stock 1,297,357 $ 0 1,297,357 D Stock Option (Right to Buy) $ 0.05 03/29/2007 J( 1 ) 311,365 ( 8 ) 11/01/2015 Common Stock 311,365 $ 0 311,365 D Stock Option (Right to Buy) $ 0.05 03/29/2007 J( 1 ) 311,365 ( 9 ) 01/01/2016 Common Stock 311,365 $ 0 311,365 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Pfost Dale R EXEGENICS INC. 4400 BISCAYNE BOULEVARD, SUITE 900 MIAMI, FL33137 President Signatures /s/ Dale R. Pfost 03/30/2007 Signature of Reporting Person Date

Explanation of Responses:

( 1 )All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc. ( 2 )1,081,116 of these shares are owned jointly by Mr. Pfost and his wife. ( 3 )These shares are currently exercisable and do not expire. ( 4 )These warrants are currently exercisable. ( 5 )These options are fully vested. ( 6 )349,657 of these options are fully vested. The balance will vest monthly until fully vested in December 2007. ( 7 )675,705 of these options are fully vested. The balance will vest monthly until fully vested in February 2009.. ( 8 )103,785 of these options are fully vested. The balance will vest monthly until fully vested in November 2009. ( 9 )90,814 of these options are fully vested. The balance will vest monthly until fully vested in January 2010.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.